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 Abstract 
  Background:  Novel biomarkers are important for identifying as well as differentiating subcorti-
cal vascular dementia (SVD) and Alzheimer’s disease (AD) at an early stage in the disease pro-
cess.   Methods:   In two independent cohorts, a multiplex immunoassay was utilized to analyze 
90 proteins in cerebrospinal fluid (CSF) samples from dementia patients and patients at risk of 
developing dementia (mild cognitive impairment).   Results:   The levels of several CSF proteins 
were increased in SVD and its incipient state, and in moderate-to-severe AD compared with the 
control group. In contrast, some CSF proteins were altered in AD, but not in SVD. The levels of 
heart-type fatty acid binding protein (H-FABP) were consistently increased in all groups with 
dementia but only in some of their incipient states.   Conclusions:   In summary, these results 
  support the notion that SVD and AD are driven by different pathophysiological mechanisms 
reflected in the CSF protein profile and that H-FABP in CSF is a general marker of neurode-
generation.    Copyright © 2011 S. Karger AG, Basel 
  Published online: January 14, 2011 
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 Introduction 
 Age is the major risk factor for developing different types of dementia ,  thus disease prev-
alence increases significantly with increasing life expectancy   [1]  . Today, only symptomatic 
treatment is available for patients with Alzheimer’s disease (AD), the most common type of 
dementia. However, promising medical treatment strategies carry hope for disease-modify-
ing therapies, and when these become available, it will be of great importance to have bio-
markers that can aid in the diagnosis and monitoring of treatment efficacy. For correct treat-
ment and to provide clinical drug trials including subjects at risk of developing a specific 
disease, it is also crucial to be able to detect and discriminate between different dementia 
forms preferably at a preclinical stage   [2, 3]  . In addition, as there are treatment strategies for 
vascular cognitive impairment, the second most common type of dementia, it is of great im-
portance to identify vascular causes of cognitive impairment at an early stage   [4] .  Biochem-
ical studies of subjects with mild cognitive impairment (MCI), a transitional state which 
might vary from normal aging to dementia   [5]  , are therefore important. Previous studies 
have shown that some biomarkers are altered before symptomatic disease presents clinically 
  [3, 6]  , but the identification of new markers is still warranted.
    The metabolism in the brain is believed to be reflected in the composition of the cere-
brospinal fluid (CSF), which makes CSF an ideal source for biomarkers related to dementia. 
In the present study, CSF levels of 90 different proteins were investigated for their potential 
as biomarkers differentiating healthy controls from three different types of dementia, i.e. 
subcortical vascular dementia (SVD), AD, and mixed types of dementias (MD), in both 
their incipient (before dementia) and overt (dementia) states. SVD is predominantly char-
acterized by small vessel disease and brain oxygen deficiency, leading to white matter le-
sions, lacunar infarcts, and incomplete ischemic injury  [7] . AD is a progressive neurodegen-
erative disorder that is neuropathologically characterized by abnormal accumulation of 
intraneuronal neurofibrillary tangles and extracellular amyloid plaques throughout the 
cortical and limbic brain regions  [8] . The etiologies of SVD and AD may be distinct but they 
also co-exist as MD   [9] .
  Here, we tested the diagnostic and discriminative power of a recently developed multiplex 
immunoassay of 90 CSF proteins in two independent cohorts: patients with dementia and 
those at risk of developing dementia. The results indicate that the profiles of the measured 
CSF proteins differ at a group level depending on the established diagnosis and severity of 
dementia. These findings are promising but need to be confirmed in independent studies.
  Materials  and  Methods 
  CSF from Gothenburg Subjects 
  At baseline, the study group consisted of 52 controls, 8 subjects with SVD, 24 subjects 
with probable AD, 14 subjects with MD, and 152 subjects with MCI. During either an obser-
vational time of 2 (n = 77) or 4 years (n = 75), depending on the time of enrollment into the 
study, 7 of the MCI subjects progressed to SVD (MCI-SVD), 15 progressed to AD (MCI-AD), 
10 progressed to MD (MCI-MD), 8 were considered to recover (MCI-norm), while 112 had 
stable disease (stable MCI;   table 1  ).
    Lumbar puncture was performed in the morning under standard conditions. Twelve 
milliliters of CSF were collected in polypropylene tubes and gently mixed to avoid gradient 
effects. CSF samples with   1 500  erythrocytes/   l were excluded, which is important to avoid 
contamination with blood proteins. All samples were centrifuged to remove cells and debris, 
and stored in aliquots at –80    °    C pending biochemical analysis.33
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    This study is a part of the Gothenburg MCI study for which the diagnostic procedure 
has been described in detail previously   [10]  . The procedure for establishing an MCI diagno-
sis was congruent with the recommendations laid down by the International Working Group 
on Mild Cognitive Impairment   [11]   and was in agreement with the MCI criteria defined by 
Petersen   [5]  . The diagnosis of dementia was based on the DSM-III-R criteria   [12]   together 
with the criteria of NINCDS-ADRDA   [13]   and ICD-10   [14]   with regard to AD, the criteria of 
Erkinjuntti et al.  [15]   with regard to SVD, and ICD-10 with regard to MD (AD with cerebro-
vascular lesions).
    Controls were not included if they had subjective or objective signs of a cognitive disor-
der assessed according to the procedure described above. To be part of this substudy, controls 
should have CSF/serum albumin ratios [CSF-albumin (mg/l) divided by serum albumin 
(g/l)]   !  10.2, thus reflecting an intact blood-brain barrier function. 
    The cognitive status was examined using the Mini-Mental State Examination (MMSE). 
The Ethics Committee at the University of Gothenburg approved the study. All patients or 
their relatives gave informed consent for participation in the study, which was conducted in 
accordance with the provisions of the Declaration of Helsinki.
    CSF from the Oxford Project to Investigate Memory and Aging  
  At baseline, the Oxford Project to Investigate Memory and Aging (OPTIMA) study 
group consisted of 48 healthy controls, 63 patients with AD (56 definitive and 7 probable), 9 
subjects with MCI who progressed to AD, and 7 controls who progressed to MCI (  table 2  ).
  Lumbar puncture was performed in the morning, as described previously  [16] . Ten to 15 
ml of CSF were collected in polystyrene tubes. CSF samples with visible red color were ex-
cluded. All samples were centrifuged to remove cells and debris, and any samples disclosing 
red cells in the sediment were discarded. Aliquots of the supernatant were transferred to 
polypropylene tubes for storage at –80    °   C.
  This study is a part of the OPTIMA project, for which the clinical and histopathological 
procedures for AD diagnosis have been described previously   [17]  . All 63 AD patients were 
diagnosed histopathologically as definite/probable AD at autopsy. MCI diagnosis was estab-
lished using the criteria outlined by Petersen   [5] .
Table 1. P  atients’ characteristics and demographics for the Gothenburg MCI study
Groups Subjects, n
(F/M)
Age
years
p value MMSE at
baseline
p value MMSE at
follow-up
p value
Control 52 (31/21) 67 (63–73) 30 (29–30) 29 (29–30)
Mild AD 24 (18/6) 65 (58–69) 0.658 26 (22–27) <0.0001 21 (14–24) <0.0001
MD 14 (7/7) 72 (65–76) 0.023 23 (21–24) <0.0001 17 (11–22) <0.0001
SVD 8 (2/6) 72 (67–75) 0.064 26 (25–26) <0.0001 23 (21–29) 0.002
Stable MCI 112 (55/57) 62 (57–68) 0.020 29 (28–30) 0.005 29 (28–30) 0.608
MCI-AD 15 (10/5) 66 (61–71) 0.679 28 (27–28) <0.0001 25 (23–26) <0.0001
MCI-MD 10 (8/2) 69 (60–74) 0.521 29 (25–29) 0.002 21 (20–25) <0.0001
MCI-SVD 7 (3/4) 68 (67–74) 0.069 28 (27–29) 0.006 26 (25–28) 0.006
MCI-norm 8 (4/4) 60 (58–62) 0.142 29 (28–30) 0.075 30 (30–30) 0.095
M  edians with interquartile ranges (25th to 75th percentiles in parentheses) are shown. The Mann-
Whitney test was used to investigate group differences, and each patient subgroup was compared with the 
control group. Follow-up lasted 2–4 years.34
Dement Geriatr Cogn Disord Extra 2011;1:31–42
 DOI:  10.1159/000323417 
EXTRA
  Öhrfelt et al.: Screening for New Biomarkers of SVD and AD 
www.karger.com/dee
    © 2011 S. Karger AG, Basel
  Published online: January 14, 2011 
    Controls were not included if they had subjective or objective signs of a cognitive disor-
der, which was assessed using CAMCOG, the cognitive test component of CAMDEX (the 
Cambridge Examination for Mental Disorders in the Elderly)   [18]  , which allows an MMSE 
score to be derived. All subjects were assessed by the CAMCOG once a year, but classifica-
tion of controls is restricted to those who continued to score above the cutoff (80) for cogni-
tive impairment.
  Ethical approval for the study was given by the Central Office for Research Ethics Com-
mittees of the National Health Service (No. C1656). All patients or their relatives gave in-
formed consent for participation in the study, which was conducted in accordance with the 
provisions of the Declaration of Helsinki.
    For both (the Gothenburg and OPTIMA) studies, CSF taken at baseline was analyzed.
    Bead-Based Luminex xMAP Technology 
 The concentrations of 90 proteins were determined on blinded samples using a multiplex 
bead-based service [HumanMAP   version 1.6 kit; Rules-Based Medicine; http://www.rules-
basedmedicine.com/products-services/humanMAP-antigen.asp with a minor modification 
(also including interleukin-18 but not interferon-     in the Gothenburg study)] at the service 
providers’ facilities in Austin, Tex., USA. This protein panel includes acute phase proteins, 
growth factors, hormones, tissue markers, vascular factors as well as proteins involved in the 
angiogenesis, blood hemostasis, immune responses, and lipid metabolism. Many of the pro-
teins have multiple biological functions and can be classified within several of the above 
groups.
    In brief, the xMAP technology is based on flow-cytometric separation of the antibody-
coated microspheres that are labeled with a specific mixture of two fluorescent dyes. After 
binding of a biotinylated reporter antibody, quantification is made by binding of a third flu-
orochrome coupled to streptavidin. The technique allows multi-analyte testing of one single 
sample.
    To be included in the study, analyte concentrations should be measurable, i.e. exceeding 
the limit of detection in   1  50% of all the samples for each respective analyte. These criteria 
were fulfilled by 44 analytes in the Gothenburg study and 45 analytes in the OPTIMA study, 
and for these analytes values below the limit of detection were conservatively set to this limit.
  Statistical  Analyses 
  All univariate statistical analyses were performed using the Statistical Package of the 
Social Sciences (SPSS). Because the distributions of most analytes were not normal (Shapiro-
Table 2.   Patients’ characteristics and demographics for the OPTIMA study
Groups Subjects, n
(F/M)
Age
years
p
value
MMSE
baseline 
p
value
CAMCOG
baseline
p
value
Control 48 (22/26) 69 (64–78) 29 (29–30) 101 (98–102)
Moderate-severe ADa 63 (40/23) 76 (67–81) 0.031 12 (7–16) <0.0001 42 (20–60) <0.0001
MCI-AD 9 (5/4) 72 (62–74) 0.553 25 (23–26) 0.0003 89 (84–91) <0.0001
Control-MCI 7 (5/2) 68 (65–69) 0.595 30 (28–30) 0.860 99 (96–102) 0.354
M  edians with interquartile ranges (25th to 75th percentiles in parentheses) are shown. The Mann-
Whitney test was used to investigate group differences, and each patient subgroup was compared with the 
control group.
a The 63 subjects with AD were diagnosed histopathologically with definite or probable AD.35
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Wilk test, p   !   0.05), non-parametric statistics were used for the analysis. Data are given as 
medians (interquartile ranges) and percent difference, i.e. 100  !  [(the median for each diag-
nostic group – the median for the control group)/the median for the control group]. The 
Mann-Whitney test was used to investigate group differences, and each subgroup of patients 
was compared with the control group. Since for each comparison 44 (Gothenburg) or 45 
(OPTIMA) analytes were statistically tested, a false discovery rate was estimated using the 
method of Benjamini and Hochberg   [19]  . This rate is the expected proportion of false dis-
coveries amongst the rejected hypotheses and characterized by a Q value, the largest false 
discovery rate for which an analyte would be positive.
    Correlations were calculated using the Spearman two-tailed correlation test. Since mul-
tiple correlations were performed, the significance level threshold was more stringently set 
to p   !   0.01.
    Large data sets are inherently hard to overview, and to better extract information from 
the immunochemical results a multivariate discriminant analysis (DA) was performed using 
the orthogonal projections to latent structures (OPLS) algorithm  [20, 21]  implemented in the 
software SIMCA P+ (version 12; Umetrics, Umeå, Sweden). This method considers all data 
at the same time in one analysis and constructs a model that maximizes the separation be-
tween different predefined groups. Prior to analysis, each patient group was randomly sub-
divided into training (80%) and prediction subsets (20%), of which only the training sets were 
used for model construction. For each OPLS-DA analysis, a first model was constructed us-
ing data for all the measured proteins that passed the inclusion criteria (see above). Then the 
final number of analytes used in the models was determined by first deleting all but the five 
analytes that contributed most to the separation, based on the variable importance in the 
projection. Further stepwise reduction was performed until a maximum of the goodness of 
prediction value (Q  2  ), resulting from cross-validation   [22]  , was reached. Stability of the final 
models was tested by external validation in which the similarity between data from the pre-
diction and training sets were judged using the Mann-Whitney test, with p  !  0.05 indicating 
a difference between the training and predictions sets.
    The relationship between sensitivity and specificity for the different groups of patients 
versus the controls was described using receiver-operating characteristic (ROC) analysis. 
The optimal cutoff value from the ROC curve was chosen as the point at which the Youden 
  [23]   index is maximal. ROC statistics were calculated based on the training and prediction 
data sets combined.
  R e s u l t s  
 Even though neither age nor MMSE differed significantly between the control groups in 
the Gothenburg and OPTIMA studies (  tables 1  ,   2  ), there were large differences in many of 
the measured protein levels between the groups. Also, both age and MMSE differed signifi-
cantly (p  !  0.0001) between the AD subjects from the two centers. For these reasons, statisti-
cal group comparisons were only made on subjects from the same center.
  Univariate  Statistical  Analysis 
  Compared with controls, MD and SVD patients had significantly increased levels of    1 -
antitrypsin (AAT; 64 and 86%, respectively), apolipoprotein H (ApoH; 40 and 61%, respec-
tively), plasminogen activator inhibitor-1 (PAI-1; 33 and 47%, respectively), and tissue in-
hibitor of metalloproteinase-1 (TIMP-1; 36 and 34%, respectively). For all of these four pro-
teins, the levels were also significantly increased in patients with MCI who progressed to MD 
or SVD (  fig. 1  a–d, online suppl. table 1, www.karger.com/doi/10.1159/000323417). In addi-36
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  Fig. 1.  Box plots of CSF proteins that differed most between controls and different stages of MD and SVD. 
Within the Gothenburg study, the levels of AAT ( a ), ApoH ( b ), PAI-1 ( c ), TIMP-1 (  d ), and H-FABP ( e ) from 
control individuals (n = 52) and patients with AD (n = 24), MD (n = 14), SVD (n = 8), MCI-AD (n = 15), 
MCI-MD (n = 10) and MCI-SVD (n = 7). The lower, upper and the middle lines of boxes correspond to 
25th and 75th percentiles and medians, respectively. The whiskers at the top and bottom extend from the 
95th and 5th percentile, respectively. 
  Fig. 2.  Multivariate analysis using OPLS-DA. For the Gothenburg study, controls (n = 50) were compared 
to MD and MD+SVD (n = 22;   a  ), MCI-(MD+SVD) (n = 17;   b  ), mild AD (n = 24;   c  ), and MCI-AD (n = 15; 
  d  ). For OPTIMA, controls (n = 48) were compared to moderate-severe (mod-sev) AD (n = 63;   e  ). P and T 
denote prediction and training sets, respectively. The dotted lines represent the optimal cutoff-based ROC 
analysis (see table 3). Corresponding variable importance in projection (VIP) plots (  f–j  ) illustrate the 
  relative contributions of the analytes to the separation between the groups. AFP =     -fetoprotein; CRP = 
C-reactive protein. 37
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tion, the levels of AAT, ApoH, and TIMP-1 were significantly increased in patients with 
moderate-severe AD (36, 29 and 5%, respectively; OPTIMA), but not in patients with mild 
AD     within the Gothenburg study compared with the control group (online suppl. table 1).
  The levels of heart-type fatty acid binding protein (H-FABP) were significantly increased 
in patients with mild AD (46%) moderate-severe AD (47%), MD (113%), SVD (49%), MCI-
AD (Gothenburg; 108%) and MCI-MD (94%) compared with the control group (  fig. 1  e, on-
line suppl. table 1). Similarly, the levels of lipoprotein(a) were significantly increased in pa-
tients with mild AD (31%), MD (59%), SVD (59%), MCI-AD (OPTIMA; 68%), MCI-MD 
(46%), and MCI-SVD (82%) compared with the control group (online suppl. table 1).
    The levels of soluble tumor necrosis factor receptor 2 (TNFR2) were significantly in-
creased in patients with mild AD (15%) and moderate-severe AD (15%), MD (41%) and MCI-
SVD (40%) compared with the control group (online suppl. table 1). 
    The levels of thyroid-stimulating hormone (TSH) were significantly altered in patients 
with mild AD (46%) and moderate-severe AD (–40%), MCI-AD (Gothenburg; 81%) and 
MCI-SVD (169%) compared with the control group (online suppl. table 1).
  Many proteins were significantly altered in patients with moderate-severe AD compared 
with the control group, e.g.     -fetoprotein (11%), calcitonin (108%), C-reactive protein (57%), 
ENRAGE (50%), and vascular endothelial growth factor (VEGF; –19%), but they were un-
changed in mild AD. In contrast,    2 -microglobulin (   2 m) levels were significantly increased 
in patients with mild AD (30%) compared with the control group, but not in moderate-severe 
AD (online suppl. table 1).
  Multivariate  Statistical  Analysis 
 The different patient groups, MD+SVD, MCI-(MD+SVD), mild AD, MCI-AD (Gothen-
burg), and moderate-severe AD were compared to controls using multivariate DA, and the 
results are shown in   figure 2  ; the corresponding ROC analysis is summarized in   table 3  . All 
dementia subgroups were significantly different (p   !   0.0001) from the controls (  fig. 2  a–e), 
although due to different proteins (  fig. 2  f–j). Almost all of these proteins were lower in the 
control group than in the dementia groups. The only exceptions were prostatic acid phos-
phatase (PAP) in mild AD (  fig. 2  h) and VEGF in moderate-severe AD (  fig. 2  j), which were 
both lower compared to controls.
Table 3.   Group comparisons based on results from the multivariate discriminant analysis
Controls/
patients
Sensitivity Specificity AUC 
Control and MD+SVDa 52/22 86 (65–97) 86 (73–94) 0.88 (0.79–0.97)
Control and MCI-(MD+SVD)a  52/17 88 (64–99) 74 (60–85) 0.83 (0.72–0.94)
Control and mild ADa 52/24 79 (58–93) 72 (58–84) 0.79 (0.68–0.90)
Control and MCI-ADa 52/15 73 (45–92) 88 (76–95) 0.86 (0.77–0.96)
Control and moderate-severe ADb 48/63 68 (55–79) 95 (85–99) 0.86 (0.80–0.93)
R OC curve analysis with the area under the curve (AUC) calculated using data from both training and 
prediction sets. Analysis is based on the corresponding models in figure 2; 95% confidence intervals are 
given in parentheses.
a Controls (n = 50) and patients from the Gothenburg study: MD+SVD (n = 22), MCI-(MD+SVD)
(n = 17), AD (n = 24), and MCI-AD (n = 15).
b Controls (n = 48) and AD subjects (n = 63) from the OPTIMA study.39
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    There was a high sensitivity (86%) for detecting MD+SVD and also a high specificity 
(86%) for discriminating MD+SVD from the control group (  fig. 2  a;   table 3  ). Both H-FABP 
and AAT contributed to the separation between the two groups (  fig. 2  f), which is in agree-
ment with the univariate analyses showing increased levels of these proteins in patients with 
MD or SVD compared with controls. There was also a high sensitivity (88%) for detecting 
MCI-(MD+SVD) and a moderate specificity (74%) for discriminating MCI-(MD+SVD) 
from the control group (  fig. 2  b;   table 3  ). PAI-1, RANTES, TIMP-1, and lipoprotein(a) con-
tributed to the separation between the two groups (  fig. 2  g).
    The combination of 5 proteins, H-FABP, TNFR2,     2  m, PAP, and TSH, helped to dis-
criminate mild AD from controls with a sensitivity and specificity of 79 and 72%, respec-
tively (  fig. 2  c, h;   table 3  ). The corresponding figures for MCI-AD (Gothenburg) were 73 and 
88% (  table 3  ), respectively, with equal contribution of H-FABP and TSH to the separation 
(  fig. 2  d, i). These two proteins were already different in the MCI-AD (Gothenburg) group 
( fig. 1 d,  i).
  For the OPTIMA study, multivariate analysis enabled to distinguish between moderate-
severe AD and controls with sensitivity and specificity estimates of 68 and 95%, respectively. 
Only H-FABP was among the five analytes that contributed most to the separation between 
AD and controls in both the Gothenburg and the OPTIMA studies (  fig. 1  h, j).
    Internal and external validations were performed to assess the stability of the multivar-
iate models and both tests indicate, based on the criteria given in Materials and Methods, 
that the separation is not due to overfitted models (  fig. 2  a–e).
    There was no general statistically significant correlation between the albumin ratio and 
the panel of analyte concentrations within any of the diagnostic groups. Only a few patients 
with MD, SVD, and their incipient states had albumin ratios above the highest reference 
value (data not shown).
  Discussion 
  In this study, the concentrations of 90 different proteins were assessed in the CSF from 
healthy controls and patients with dementia at different stages, and the results suggest that the 
protein profile differs between disorders and is dynamic in the disease process. For MD and 
SVD, the CSF levels of AAT, TIMP-1, PAI-1, and ApoH were all increased compared to healthy 
controls. AAT is an acute phase protein that is involved in inflammatory responses   [24]   and 
TIMP-1 is a major regulator of extracellular matrix synthesis/degradation and participates in 
angiogenesis and inflammatory responses   [25]  . PAI-1 is a regulator of fibrinolysis   [26] ,  and 
ApoH also prevents activation of the blood coagulation cascade   [27]  . Interestingly, the levels 
of these proteins were altered in a disease-specific manner already at the MCI stage in patients 
that later had MD or SVD, indicating that changes in the processes are relatively early events 
in the etiology of these disorders. Both inflammatory   [28]   and hemostatic factors   [29]   have 
previously been suggested to be involved in the etiology of different types of dementia.
    In contrast, the levels of AAT, ApoH, and TIMP-1 were significantly increased only in 
patients with severe AD, but not in the cohorts with incipient or mild AD. However, since 
there was a large difference in age between the patients with severe AD and the other groups, 
an age effect on the protein levels cannot be excluded.
  A very consistent finding was the increase in H-FABP in all groups, except for MCI-SVD, 
compared with controls. H-FABP functions in the intracellular lipid metabolism by carrying 
fatty acids, and elevated CSF levels of this protein have previously been reported in studies 
on dementia and Creutzfeldt-Jakob disease  [30] , which suggests that H-FABP in CSF is a gen-
eral marker for neurodegeneration.40
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    Other proteins that differed in some groups compared to the controls include TNFR2, 
which was recently shown to be increased in patients with MCI developing AD and vascular 
dementia   [31]  , and TSH, a hormone that activates the thyroid gland. Elevated TSH levels in 
blood samples have previously been associated with dementia   [32] .
  As expected, the multivariate model achieved better separation than the separate analy-
sis of each analyte, as judged from the ROC analysis. The analytes that differed already in 
the univariate analysis, as discussed above, also presented as important variables for the 
separation between different groups. 
    None of the proteins that contributed most to the separation between MD+SVD and 
controls did so at the MCI stage. This might be due to the heterogeneity caused by combin-
ing MD and SVD cases, but also by different contributions of SVD and AD in the MD cases. 
However, it may also imply that the protein profile in CSF is dynamic depending on the stage 
of the disease. If so, the profile could be a valuable tool for determining disease progression 
in MD and SVD. In contrast, for AD both H-FABP and TSH contribute to the discrimina-
tion already at the MCI stage, which suggests a timeline where changes in H-FABP and TSH 
precede alterations in TNFR2,     2  m, and PAP in the disease process.
    There was no consistent correlation between the albumin ratio and panel analyte con-
centrations within any of the diagnostic groups, which suggests that the measured CSF pro-
tein concentrations are not influenced by leakage across the blood-brain barrier. Only a few 
patients within the group of MD+SVD and their incipient state had albumin ratios above the 
highest reference value (data not shown). This is contradictory to previous studies that have 
shown that blood-brain barrier functions are impaired in dementia with white matter chang-
es   [33] .
    A limitation of the present study is that in the control groups from the Gothenburg and 
OPTIMA cohorts the measured levels of several proteins analyzed differed significantly, 
which prohibited combining of the two cohorts. As a consequence, the Gothenburg data did 
not perform well in the OPTIMA model and vice versa (data not shown). The reason for the 
difference is presently unknown but pre-analytical factors, e.g. sample handling, may con-
tribute to the variation. The observed center-to-center variation is not unique, and in a recent 
large multicenter study the need for a standardized protocol for clinical procedures was pro-
posed to eliminate confounding factors that render comparisons of studies from different 
centers difficult   [34] .
  Conclusions   
  The present results suggest that the pathological changes, reflected in the CSF composi-
tion, occur several years before clinical symptoms manifest. However, future studies with a 
longitudinal design are required to establish the potential use of the analytes investigated as 
biomarkers.
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